Diflucan Partnership
Goal: To provide treatment for AIDS-related fungal infections in developing countries where HIV/AIDS is endemic
Targeted Area: Developing countries with priority given to those countries with greater than 1 percent HIV/AIDS prevalence
Start Date: 2000
Pfizer's Commitment: To provide Diflucan® (fluconazole) for the treatment of two fungal opportunistic infections associated with HIV/AIDS, free of charge to government and nongovernmental organizations in developing countries with greater than 1% HIV/AIDS prevalence.
Partners: Direct Relief International (DRI), International Dispensary Association (IDA), governments and NGOs
Successes:
- More than $1.1 billion in medicine donated to more than 2400 sites in 63 countries in Africa, Asia, the Caribbean and Latin America
- More than 20,000 health professionals trained in the diagnosis and treatment of fungal opportunistic infections
 |
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page. |
Learn more about the Diflucan Partnership Program.
- Find out how to apply. Visit www.directrelief.org/diflucanpartnership
- Diflucan Partnership fact sheet
- Contact Us
- Investors
- Sitemap
- Careers
- Business to Business
- Terms of Use
- Global Network
- Privacy Policy
Copyright © 2002–2010 Pfizer Inc. All rights reserved. This information is intended only for residents of the United States. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries. Pfizer Inc is a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.
